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ew Approaches to
emodynamic Measurement
ool Devices But a Shaky Infrastructure*
arc A. Silver, MD, FACC
ak Lawn, Illinois
Life is like laying a foundation; you have to build it
brick by brick.
Sam Silver (personal communication, June 1960)
Confusion of goals and perfection of means seems, in my opinion,
to characterize our age.
Albert Einstein (1)
rguably late, long after initial heart muscle damage, early
ellular, structural, and neurohormonal changes, almost all
eart failure can be described, in part, by hemodynamic
bnormalities. And knowledge or estimation of a patient’s
emodynamic state allows a formulation of a fuller thera-
eutic plan. Oftentimes the plan incorporating a hemody-
amic profile may alter the natural disease progression for a
atient (2).
See page 2375
Given the potential to alter a serious disease state,
ccurate and instantaneous knowledge of patient’s central
emodynamics continues to intrigue all who treat these
atients. And so the literature has hosted a debate whether
nowledge of an individual’s hemodynamics during a small
napshot of time is indeed efficacious (3,4). What may have
een on trial, however, is more the evidence base for how to
eact to a variety of hemodynamic profiles rather than the
afety or efficacy of the pulmonary artery catheter technol-
gy itself (4).
Recently, the intrigue with knowing a patient’s hemody-
amic profile has been investigated with either noninvasive
5,6) impedance cardiography technology or by adding such
echnology to a device commonly implanted in target
atients (7). These early studies have enlightened us, at
east, to the false premise of presuming that a 1-, 2-, or
-day snapshot of a patient’s hemodynamics using a pul-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
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From the Heart Failure Institute and the Department of Medicine, Advocate
hrist Medical Center, Oak Lawn, Illinois.onary artery catheter at the time of admission to a critical
are unit is indeed any form of “gold standard.” We
evertheless continue to ask the same questions of any new
echnology seeking to provide us with a patient’s hemody-
amics. First, what is its ease of use (compared with the
ulmonary artery catheter)? Second, how well does it corre-
ate with the pulmonary artery catheter during a period of
ecompensation? Third, how safe is it to use (in comparison
o the pulmonary artery catheter)? Fourth, if it is being used
erially or indeed implanted, how much time before a
ecompensation does it provide warning signals? And fifth,
nd perhaps most importantly, if the goal of monitoring is
o reduce morbidity and improve survival, then if the
arning signals are heeded and appropriate therapy applied,
oes it do so?
In this issue of the Journal, Verdejo et al. (8) report of still
nother device seeking to answer many of these questions,
hich continues the intrigue in knowing a patient’s hemo-
ynamics. The authors describe a feasibility trial of the
ardioMEMS Heart Failure Sensor (CardioMEMS Inc.,
tlanta, Georgia), which is a novel catheter-delivered pres-
ure sensor that is chronically implanted in the pulmonary
rtery. Alterations in the pressure inside of the artery alters
he baseline resonant frequency emitted by the device and
hen, using an external sensor, the signal is transmitted
utside of the body and transduced into a waveform. The
xternal device similarly calibrates for external pressure. The
uthors describe their experience in 12 patients who had the
evice implanted and begin to answer several of our ques-
ions. Although we know little about how these 12 patients
ere selected, they are fairly well characterized in a table,
nd, interestingly, the patients included provide an oppor-
unity to study this device in a fairly broad range of
ulmonary artery pressures (mean from 25 to 60 mm Hg).
In terms of ease of use, the authors indicate successful
lacement in all 12 patients with an average implant time of
pproximately 70 min but notably as little as 19 min. A
ingle device migration occurred without untoward effects
nd presumed continued function.
The bulk of the report and figures seek to answer questions
f correlation with either echocardiography-derived pulmonary
rtery pressures or hemodynamics directly measured with a
ulmonary artery catheter. These show strikingly good corre-
ation coefficients in the short and medium terms. Unan-
wered, but sure to be the focus of future clinical trials with this
ew device, are questions 4 and 5. The authors provide a good
iscussion of the added value of such a device that can provide
eal-time evaluation of an accurate pulmonary artery pressure.
So, besides the 2 unanswered questions for this device
nd others of its genre, there really are 2 additional
overriding” questions from which we should not be dis-
uaded. We are always excited to welcome new technology
o our diagnostic and potentially therapeutic armamentar-
um; we need, however, to be aware that such devices herald
n a new era where serial recording of the patient in a
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ween may now be available. We need to sort out how and
hen to retrieve these signals, how to incorporate them into
aily clinical routines and disease management strategies,
nd how to use information technology to help us decide
hat signals are the actionable early warning signs of a
atient with a forthcoming clinical event (question 4). The
evices without a suitable infrastructure will overwhelm the
octors and nurses monitoring these devices, and any
otential benefit will be obscured by the burden of the data
oad. In addition, the sub rosa issue of responsibility and
iability for data review and therapeutic decisions is just
eginning to surface. Clearly there is a call to action for us
o develop the infrastructure needed to incorporate the
nformation era of heart disease management into a new and
xpanded definition of “integrated disease management
rograms.”
But are we not begging the question? What is needed is
ore insight and consensus on how to rapidly respond to
ither the early warning signal of decompensation or that of
ate, advanced decompensation for that matter. Any metric
r meter is simply diagnostic. It puts before the clinician
nformation that must be integrated and acted upon. Each
ay I am amazed at how different are the responses to the
ame clinical scenario. Guidelines notwithstanding, clinical
ariability abounds in heart failure care. The variability,
oupled with a mystical presumption of therapeutic effec-
iveness of simply having hemodynamic measurements,
emain the very stumbling blocks of our foundation upon
hich we need to design the building of improved outcomes
or our patients. So I, as do we all, welcome the engineering
nd technological advances that are leading us to new and
etter ways to know a patient’s hemodynamic profile,erhaps even continuously, but we should not forget to
reate, in parallel, the knowledge base, which will allow us
o capitalize on these new advances.
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